References
- Volpe M, Savoia C, De Paolis P, Ostrowska B, Tarasi D, Rubattu S. The renin–angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol. 2002;13 Suppl 3:S173–S178.
- Kjeldsen SE. Direct renin inhibition with focus on aliskiren and cardiovascular outcome studies. Short article. Eur Cardiovasc Dis. 2006:2–6.
- Weir MR, Dzau VJ. The renin–angiotensin–aldosterone system: A specific target for hypertension management. Am J Hypertens. 1999;12:205S–213S.
- Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med. 1957;106:439–453.
- Wood JM, Cumin F, Maibaum J. Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol Ther. 1994;61:325–344.
- Rahuel J, Rasetti V, Maibaum J, Rueger H, Goschke R, Cohen NC, et al.Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem Biol. 2000;7:493–504.
- Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, et al.Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698–705.
- Parving H-H, . The Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). ESC. 2012; Abstract 399.
- Azam U. Direct healthcare professional communication on potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes and renal impairment and/or cardiovascular disease treated with aliskiren (Tekturna®) tablets and aliskiren-containing combination products. East Hanover, NJ: Novartis Pharmaceuticals Corporation.